Skip to main content
Signal8
Launch Terminal

ANGIODYNAMICS INC (ANGO)

AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Instruments & Supplies

AngioDynamics, Inc. logo

AngioDynamics, Inc.

NASDAQ:ANGOHealthcare
-2.91%$11.99
AH$11.99+0.00%vs close
Mkt Cap$504.23M
Float36.63M
O/S42.05M
Vol
$ Vol
RVOL
Inst Own90.5%
SI5.2%
Earnings
Dilution
AngioDynamics, Inc. logoNASDAQ:ANGO$11.99-2.91%
Phase Distribution
22 lead-sponsored trials·5 active·8 completed
Phase 22
Phase 31
Phase 41
Not applicable18
(13 more as collaborator)
Status Overview
Not yet recruiting5
Recruiting3
Active, not recruiting2
Completed8
Stopped3
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Recruiting

    Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone

    Auryon Atherectomy System, Balloon Angioplasty

    Peripheral Arterial Diseases

    Enrollment
    224
    Start
    Apr 2025
    Primary Completion
    Feb 2029est.
    Completion
    Apr 2029est.
    NCT06777901
  • Phase 3
    Active, not recruiting

    A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer

    Modified FOLFIRINOX Regimen

    Stage III Pancreatic Cancer

    Enrollment
    528
    Start
    Feb 2021
    Primary Completion
    Apr 2025est.
    Completion
    Apr 2025est.
    NCT03899636
  • Phase 2
    Completed

    Radiofrequency Ablation of Pulmonary Tumors Response Evaluation

    RF ablation (Rita Medical Systems Model 1500x)

    Non Small Cell Lung Cancer, Pulmonary Metastases

    Enrollment
    106
    Start
    Jul 2001
    Primary Completion
    Dec 2006
    Completion
    Dec 2007
    NCT00690703
  • Phase 2
    Completed

    NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer

    NanoKnife Low Energy Direct Current (LEDC) System Ablation

    Pancreatic Adenocarcinoma

    Enrollment
    10
    Start
    May 2011
    Primary Completion
    Dec 2011
    Completion
    Sep 2012
    NCT01369420
  • Observational
    Terminated

    Post-Market Observation Study of Intra-renal Drug Delivery (PROVIDE)

    Benephit catheter for Targeted Renal Therapy

    Acute Kidney Injury, Acute Renal Failure +2

    Enrollment
    -
    Start
    Feb 2010
    Primary Completion
    Dec 2011
    Completion
    Dec 2011
    NCT01064895
  • Not applicable
    Completed

    Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC)

    Ablation with the NanoKnife Low Energy Direct Current (LEDC) System

    Carcinoma, Hepatocellular

    Enrollment
    26
    Start
    Feb 2010
    Primary Completion
    Jan 2013
    Completion
    Jun 2013
    NCT01078415
  • Not applicable
    Withdrawn

    Comparison Study for Safety and Efficacy of Two Devices for the Treatment of the Great Saphenous Vein

    VNUS RF ClosureFAST, VenaCure EVLT NeverTouch

    Varicose Veins, Venous Insufficiency

    Enrollment
    0
    Start
    Jul 2010
    Primary Completion
    Feb 2011est.
    Completion
    Feb 2012est.
    NCT01173419
  • Not applicable
    Terminated

    The PROOF Study: The PICC Related Obstruction Of Flow Study

    BioFlo™ Peripherally Inserted Central Catheter (PICC), Bard® Dual-Lumen PowerPICC SOLO2®

    Patients Indicated for a PICC for Any Medical Condition

    Enrollment
    57
    Start
    Oct 2013
    Primary Completion
    Jul 2014
    Completion
    Aug 2014
    NCT01921114
  • Not applicable
    Unknown status

    Study of NanoKnife for Ablation of Prostate Cancer in Intermediate Risk Patients

    NanoKnife Procedure

    Prostate Cancer

    Enrollment
    6
    Start
    May 2021
    Primary Completion
    Nov 2022
    Completion
    May 2024est.
    NCT01972867
  • Not applicable
    Completed

    SeCure Endovenous Laser Treatment Study

    VenaCure EVLT 400 µm fiber Procedure Kit

    Chronic Venous Insufficiency

    Enrollment
    112
    Start
    Jan 2015
    Primary Completion
    Mar 2018
    Completion
    Jan 2019
    NCT02215369
  • Observational
    Completed

    Initial Experience With the AngioVac Venous Drainage Cannula

    AngioVac

    Heart Disease

    Enrollment
    51
    Start
    Feb 2016
    Primary Completion
    Sep 2016
    Completion
    May 2017
    NCT02775565
  • Observational
    Active, not recruiting

    A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer

    SOC

    Stage III Pancreatic Cancer

    Enrollment
    532
    Start
    May 2019
    Primary Completion
    Apr 2025est.
    Completion
    Apr 2025est.
    NCT03899649
  • Observational
    Completed

    Post-Market Registry of AURYON Atherectomy Device in Subjects Affected With Infrainguinal Peripheral Artery Disease

    AURYON Atherectomy System

    Infrainguinal Peripheral Artery Disease, Peripheral Arterial Disease +1

    Enrollment
    102
    Start
    Aug 2020
    Primary Completion
    Mar 2021
    Completion
    Apr 2023
    NCT04229563
  • Not applicable
    Completed

    Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

    Irreversible Electroporation

    Prostate Cancer

    Enrollment
    121
    Start
    Mar 2022
    Primary Completion
    Aug 2024
    Completion
    Aug 2024
    NCT04972097
  • Not applicable
    Completed

    Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for Treatment of Acute Pulmonary Embolism

    AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE

    Pulmonary Embolism, Acute Pulmonary Embolism

    Enrollment
    122
    Start
    Oct 2022
    Primary Completion
    Jan 2024
    Completion
    Jan 2024
    NCT05318092
  • Not applicable
    Recruiting

    Evaluating the Efficacy, Safety and Long Term Functional Outcomes of Percutaneous Mechanical Aspiration Thrombectomy for Treatment of Acute Pulmonary Embolism Using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System

    AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System

    Acute Pulmonary Embolism (PE), Pulmonary Embolism

    Enrollment
    256
    Start
    Jun 2025
    Primary Completion
    Jun 2028est.
    Completion
    Jun 2028est.
    NCT06697314
  • Not applicable
    Not yet recruiting

    International Study on Treatment of Patients With Metastatic Colorectal Liver Lesions Patients With IRE

    Irreversible Electroporation

    Colorectal Adenocarcinoma Metastatic in the Liver, Liver Ablation +1

    Enrollment
    50
    Start
    Feb 2026est.
    Primary Completion
    Feb 2028est.
    Completion
    Feb 2029est.
    NCT07191548
  • Not applicable
    Not yet recruiting

    International Study on Treatment of Liver (HCC) Patients With IRE

    Irreversible Electroporation

    Hepatocellular Carcinoma (HCC), Liver Ablation +1

    Enrollment
    50
    Start
    Feb 2026est.
    Primary Completion
    Feb 2028est.
    Completion
    Feb 2029est.
    NCT07192731
  • Not applicable
    Recruiting

    Acute Pulmonary Embolism Treatment With the AlphaVac Multipurpose Mechanical Aspiration System and the AlphaReturn Blood Management System: Evaluation of Safety and Effectiveness

    AlphaReturn Blood Management System

    Pulmonary Embolism Acute

    Enrollment
    39
    Start
    Mar 2026
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2026est.
    NCT07280247
  • Not applicable
    Not yet recruiting

    Percutaneous AngioVac Vegetation Extraction (PAVE) to Remove Right Heart Vegetations in Patients With Infective Endocarditis

    AngioVac System

    Infective Endocarditis (IE)

    Enrollment
    30
    Start
    Apr 2026est.
    Primary Completion
    Nov 2026est.
    Completion
    Mar 2027est.
    NCT07282002
  • Not applicable
    Not yet recruiting

    Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone in Europe

    Auryon Atherectomy System, Balloon Angioplasty

    Peripheral Arterial Disease

    Enrollment
    50
    Start
    May 2026est.
    Primary Completion
    May 2029est.
    Completion
    May 2030est.
    NCT07472439
  • Not applicable
    Not yet recruiting

    Irreversible Electroporation (IRE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)

    Irreversible Electroporation

    Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)

    Enrollment
    40
    Start
    Sep 2026est.
    Primary Completion
    Dec 2027est.
    Completion
    Jun 2031est.
    NCT07640776
Search ClinicalTrials.gov for “Angiodynamics”